{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:48Z","timestamp":1781671968243,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007208","name":"Vanderbilt-Ingram Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007208","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.gore.2026.102122","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:54:06Z","timestamp":1779926046000},"page":"102122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0386-8668","authenticated-orcid":false,"given":"Halle","family":"Petrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosby A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2026.102122_b0005","article-title":"Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers","volume":"63","author":"Bastin","year":"2026","journal-title":"Gynecol Oncol Rep."},{"issue":"2","key":"10.1016\/j.gore.2026.102122_b0010","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging Causes of Drug-Induced Anaphylaxis: a Review of Anaphylaxis-Associated Reports in the FDA adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.gore.2026.102122_b0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2023.08.017","article-title":"Management of chemotherapy hypersensitivity reactions and desensitization: an SGO clinical practice statement","volume":"177","author":"Hall","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2026.102122_b0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaip.2022.12.002","article-title":"Drug Allergy Practice Parameter Updates to Incorporate into your Clinical Practice","volume":"11","author":"Banerji","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"6","key":"10.1016\/j.gore.2026.102122_b0025","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a 2022 practice parameter update","volume":"150","author":"Khan","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.gore.2026.102122_b0030","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.gore.2026.102122_b0035","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity Reactions to platinum Agents and Taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"13","key":"10.1016\/j.gore.2026.102122_b0040","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.gore.2026.102122_b0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1008207025430","article-title":"Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions","volume":"8","author":"Bookman","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2026.102122_b0050","doi-asserted-by":"crossref","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (Taxol). Wood AJJ, ed. N Engl J Med. 1995;332(15):1004-1014. doi:10.1056\/NEJM199504133321507.","DOI":"10.1056\/NEJM199504133321507"},{"issue":"4","key":"10.1016\/j.gore.2026.102122_b0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/17435889.2.4.415","article-title":"Nanoparticle Albumin-Bound Paclitaxel: a Novel Cremphor-EL\u00ae -Free Formulation of Paclitaxel","volume":"2","author":"Stinchcombe","year":"2007","journal-title":"Nanomed"},{"key":"10.1016\/j.gore.2026.102122_b0060","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Published online July 16, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"issue":"33","key":"10.1016\/j.gore.2026.102122_b0065","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: final overall Survival and adverse Event Analysis of a phase III Trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.gore.2026.102122_b0070","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3390\/cancers16071282","article-title":"Temporal Trends in Treatment and Outcomes of Endometrial Carcinoma in the United States, 2005\u20132020","volume":"16","author":"Adekanmbi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.gore.2026.102122_b0075","article-title":"EpiPen STAT: a quality improvement project for anaphylaxis management","volume":"40(28_suppl):319\u2013319","author":"Sato-DiLorenzo","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.gore.2026.102122_b0080","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: a Review","volume":"334","author":"Caruso","year":"2025","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.gore.2026.102122_b0090","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Published online November 10, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf."},{"key":"10.1016\/j.gore.2026.102122_b0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fphar.2017.00800","article-title":"Risk Factors of Hypersensitivity to Carboplatin in patients with Gynecologic Malignancies","volume":"8","author":"Tai","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.gore.2026.102122_b0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MLR.0000000000001635","article-title":"Trends in Cancer Treatment Service Availability across critical Access Hospitals and prospective payment System Hospitals","volume":"60","author":"Hung","year":"2022","journal-title":"Med. Care"},{"issue":"7","key":"10.1016\/j.gore.2026.102122_b0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant Chemotherapy for newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102122_b0110","doi-asserted-by":"crossref","first-page":"e6840","DOI":"10.1002\/cam4.6840","article-title":"Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers","volume":"13","author":"Zwimpfer","year":"2024","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.gore.2026.102122_b0115","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.anai.2025.05.010","article-title":"Rapid desensitization in patients with immediate hypersensitivity to antineoplastic drugs","volume":"135","author":"Liang","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"9","key":"10.1016\/j.gore.2026.102122_b0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1159\/000530959","article-title":"Hypersensitivity Reaction and Rapid Drug Desensitization with Chemotherapeutics: a Tertiary Reference Center Experiences","volume":"184","author":"Bulut","year":"2023","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.gore.2026.102122_b0125","first-page":"1","article-title":"Real-World Outcomes of Rapid Drug Desensitization for Taxane and platinum Chemotherapy. Int Arch Allergy Immunol","author":"Sa\u011fun","year":"2026","journal-title":"Published Online January 17"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:04:29Z","timestamp":1781669069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S2352578926001025"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102122","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of anaphylactic reactions involving carboplatin and paclitaxel reported to the FDA from 1970 to 2023","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102122"}}